Treatment of Severe Hypervolemic Hyponatremia in a Child With Pneumoniadoi:10.1097/PEC.0000000000001005Poddighe, DimitriPediatric Emergency CarePoddighe D. Treatment of severe hypervolemic hyponatremia in a child with penumonia. Pediatr Emerg Care. 2017;33(1):72....
Although fluid restriction is effective in managing hypervolemic hyponatremia, the long-term compliance, particularly in out-patient, is poor. The availability of vasopressin receptor antagonists (vaptans) seemed to change the field of hyponatremia. The most studied, tolvaptan, an oral selective V2 ...
Treatment depends on several factors, including the cause, overall volume status of the patient, severity of hyponatremic symptoms, and duration of hyponatremia at presentation. Vasopressin antagonists like tolvaptan seem promising for the treatment of euvolemic and hypervolemic hyponatremia in heart ...
Although two randomized, placebo-controlled, double-blind phase III studies (SALT-1 and SALT-2) had previously shown that short-term (鈮 30-day) administration of tolvaptan safely increased serum sodium level in patients with euvolemic or hypervolemic hyponatremia, effects of long-term treatment ...
The aim of this review is to present how to differentiate hypovolemic, euvolemic and hypervolemic hypernatremias, suggesting algorithms for practical management.doi:10.3109/14767058.2011.607667Marcialis, Maria AntoniettaDessi, AngelicaPintus, Maria Cristina...
Conivaptan has been approved by the FDA for treating hypervolemic hyponatremia in syndrome of inappropriate antidiuretic hormone; however, studies specific to efficacy in cirrhosis are lacking. [16] In a multicenter study that assessed the safety and efficacy of an automated pump system for the ...
Current management practices for hyponatremia (HN) are incompletely understood. The HN Registry has recorded diagnostic measures, utilization, efficacy, and outcomes of therapy for eu- or hypervolemic HN. To better understand current practices, we analyzed data from 3087 adjudicated adult patients in ...
To reduce the risk of ischemic complications in patients with subarachnoid hemorrhage (SAH), hypervolemic therapy is generally advocated. However, such con... T Mori,Y Katayama,T Kawamata,... - 《Journa...
Currently, however, conivaptan is the only FDA approved aquaretic in the United States for use in hospitalized patients with euvolemic and hypervolemic hyponatremia. Conivaptan Chemical structure and molecular mechanism of action Conivaptan hydrochloride (Vaprisol®, Astellas Pharma US, Inc.), ...
(PCK rat), and ado- lescent nephronophthisis.146,150 Other studies have shown that tolvaptan, a vasopressin receptor antagonist FDA approved for the treatment of clinically-significant hypervolemic and euvolemic hyponatremia, may also be effective in animal models of PKD, with this drug having ...